Abstract
Neuroendocrine cancer of the prostate is considered to be a rare entity with bad prognosis and limited therapeutic options. We performed a prospective analysis of the patients treated in our hospital for prostate cancer between 1st January 2015 and 31rd December 2018. Neuroendocrine phenomena were tested by immunohistochemistry and laboratory chemistry on the request of the clinicians in the cases when a positive diagnosis was suspected. Clinical tableaux of high suspicion of neuroendocrine cancer included radiological progression of a metastatic disease without PSA rise, relatively extended metastatic disease associated to a low PSA, disease with non-pulmonary visceral metastases. 10 patients were diagnosed with neuroendocrine tumour out of 521 prostate cancers. Half of the patients had a survival over a year. 3 patients received 3 lines of efficacious palliative chemotherapy. 1 patient underwent prostatectomy after neoadjuvant chemotherapy for a localised disease. The incidence of neuroendocrine tumours among prostate cancer patients was higher than expected. Some of the patients had a relatively good outcome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Honn KV, Aref A, Chen YQ et al (1996) Prostate cancer - old problems and new approaches. (Part II. Diagnostic and prognostic markers, Pathology and Biological Aspects). Pathol Oncol Res 2:191–211
Parimi V, Goyal R, Poropatich K, Yang XJ (2014) Neuroendocrine differenciation of prostate cancer: a review (2014). Am J Clin Exp Urol 2:273–285
Li J, Wang Z (2016) The pathology of unusual subtypes of prostate cancer. Chin J Cancer Res 28:130–143
Zaffuto E, Pompe R, Zanaty M et al (2017) Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: a SEER database analysis. Clin Genitourin Cancer 15:e793–e800
Kishore K, Rafeeq A, Chime C et al (2018) Poorly differentiated small-cell-type neuroendocrine carcinoma of the prostate: a case report and literature review. Case Rep Oncol 11:676–681
Palmgren JS, Karavadia SS, Wakefield MR (2007) Unusual and underappreciated: small cell cancer of the prostate. Semin Oncol 34:22–29
Beltran H, Oromendia C, Danila DC et al (2019) A phase II trial of the Aurora kinase a inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers. Clin Cancer Res 25:43–51
Monn MF, Cheng L (2016) Emerging trend in the evaluationand management of small cell prostate cancer: a clinical and molecular perspective. Expert Rev Anticancer Ther 16:1029–1037
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors have no conflict of interest in connection with the publication of this article.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kránitz, N., Szepesváry, Z., Kocsis, K. et al. Neuroendocrine Cancer of the Prostate. Pathol. Oncol. Res. 26, 1447–1450 (2020). https://doi.org/10.1007/s12253-019-00712-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-019-00712-2